113 related articles for article (PubMed ID: 11437395)
1. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
Ueoka H; Tanimoto M; Kiura K; Tabata M; Takigawa N; Segawa Y; Takata I; Eguchi K; Okimoto N; Harita S; Kamei H; Shibayama T; Watanabe Y; Hiraki S; Harada M
Br J Cancer; 2001 Jul; 85(1):9-13. PubMed ID: 11437395
[TBL] [Abstract][Full Text] [Related]
2. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
3. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
[TBL] [Abstract][Full Text] [Related]
6. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.
Takigawa N; Fujiwara K; Ueoka H; Kiura K; Tabata M; Hiraki A; Shibayama T; Segawa Y; Kamei H; Hiraki S; Tanimoto M; Harada M
Anticancer Res; 2003; 23(1B):557-60. PubMed ID: 12680145
[TBL] [Abstract][Full Text] [Related]
7. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Masuda N; Fukuoka M; Fujita A; Kurita Y; Tsuchiya S; Nagao K; Negoro S; Nishikawa H; Katakami N; Nakagawa K; Niitani H
Br J Cancer; 1998 Jul; 78(2):251-6. PubMed ID: 9683302
[TBL] [Abstract][Full Text] [Related]
9. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
[TBL] [Abstract][Full Text] [Related]
10. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
[TBL] [Abstract][Full Text] [Related]
11. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
12. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Cardenal F; Domine M; Massutí B; Carrato A; Felip E; Garrido P; Juan O; Artal A; Barneto I; López-Vivanco G; Balcells M; Rosell R
Lung Cancer; 2003 Feb; 39(2):201-7. PubMed ID: 12581574
[TBL] [Abstract][Full Text] [Related]
13. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T
Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
Saito H; Kudoh S; Nakagawa K; Negoro S; Matsui K; Semba H; Takada M
Am J Clin Oncol; 2006 Oct; 29(5):503-7. PubMed ID: 17023787
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]